NEWS & EVENTS

Growth in Transmucosal Drug Delivery Driven by Demographic, Healthcare Trends

New Survey by Greystone Associates Examines Market Potential

(Amherst, NH) – In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism.

Demand for transmucosal drug delivery will benefit from several converging market forces. The shifting population demographics in developed societies will drive an increasing demand for palliative treatments associated with an aging patient base. Continuing efforts to control rising healthcare costs in many western countries will place a greater emphasis on home health care and self-administration of drug therapies for chronic conditions such as pain management and hormone replacement therapy.

These survey findings are contained in a new and comprehensive report: Transmucosal Drug Delivery: Systemic Therapies and Markets. “Improvements in mucoadhesion, drug solubility and permeability are expanding the number of active compounds available in transmucosal formulations”, explains George Perros, Greystone’s Managing Director. “We believe transmucosal delivery will compete with skin patches for a healthy share of the emerging market for alternative drug delivery technologies.”

The report contains a comprehensive assessment of transmucosal delivery technology and products, profiles of transmucosal market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical professionals, drug delivery market participants, and healthcare investors, the report contains all of the information necessary to understand the growing potential of transmucosal technology on systemic drug development and delivery.

Source: Greystone Associates